Evaluate Mavacamten News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EXPLORER-HCM Trial finds substantial health status improvements with mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
Share Article
Saint Luke s Mid America Heart Institute shared trial findings at American College of Cardiology’s 2021 Scientific Session
The benefits observed were amongst the largest we have ever seen from a medication to improve the symptoms, function and quality of life of patients with heart failure.
KANSAS CITY, Mo. (PRWEB)
May 20, 2021
The EXPLORER-HCM (Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) Randomized Clinical Trial has shown significant improvement in the symptoms, function, and quality of life in patients with obstructive hypertrophic cardiomyopathy (oHCM) with taking mavecamten. This comes following no major advances for treating oHCM in more than 30 years, where the p ....

United States , Kansas City , University Of Missouri , Myokardia Inc , Saint Luke Mid America Heart Institute , Saint Luke Health System , American College Of Cardiology , Heart Institute , Bristol Myers Squibb , Evaluate Mavacamten , Randomized Clinical Trial , Kansas City Cardiomyopathy Questionnaire , John Spertus , Saint Luke , Mid America Heart Institute , American College , Session Late Breaking Clinical Trials , Kansas City Cardiomyopathy , Bristol Myers , Health System , Missouri Kansas City , Press Release , ஒன்றுபட்டது மாநிலங்களில் , கன்சாஸ் நகரம் , பல்கலைக்கழகம் ஆஃப் மிச Ou ரி , துறவி லூக் நடுவில் அமெரிக்கா இதயம் நிறுவனம் ,